On February 12, Paulina Cruz-Bravo, MD and collaborators had their research published by the journal of “Academic Emergency Medicine,” titled “The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics.”
In the article, the authors note that studies using fast-acting subcutaneous (SQ) insulin analogs in diabetic ketoacidosis (DKA) have “demonstrated efficacy, safety, and cost-effectiveness, allowing treatment of mild-to-moderate (MTM)-severity DKA patients in non–intensive care unit settings.” Though, there are few emergency department (ED) -based studies and exploration of its impact on operational metrics.
Over the course of seven months, the authors collected data during their implementation of the protocol for adults with MTM-severity DKA in an urban academic ED.
In their multifaceted analysis, they conclude that “treatment of patients with MTM-severity DKA with a SQ insulin protocol was effective, demonstrated equivalent safety, and reduced ED length of stay.”
Griffey, RT, Schneider, RM, Girardi, M, et al. The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics. Academic Emergency Medicine. 2023; 00: 1- 9. doi:10.1111/acem.14685